AzTrials
AzTrials

Retina PathologyOCTA & FANCT07568704

Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images

An observational study of Retina Pathology, run by Intalight, Inc at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to evaluate the image quality and clinical utility of the OCTA images from the VG200D OCT device (investigational device) compared against the FA and ICGA images from the UWF Optos California (CA) device. Read more about this study

Who is it for?
Ages 22 years and older
Conditions the study is for
Retina Pathology
What is being tested?
Dream OCT
Type of treatment
Medical device
How many people
30 participants
Where
1 siteUnited States
Study dates
25 Mar 2026to 31 Aug 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with retina pathology

Who may be able to join

  • Subjects 22 years of age or older on the date of informed consent
  • Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  • BCVA 20/400 or better in the study eye
  • Diagnosis of retinal associated pathology by investigator with the need to have an FA and/or ICGA performed in at least one eye

Who cannot join

  • Subjects unable to tolerate ophthalmic imaging
  • Subjects not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  • Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mike Sinai, PhD contact

6198067636

mike.sinai@intalight.com

United States1 site, 1 recruiting
  • Retina Consultants of Texas

    Houston, Texas, 77401

    rebbecca Taing, BS, 713-394-7576, rebbecca.taing@retinaconsultantstexas.com

    David Brown, MD

    Recruiting

Other trials in United States

About this study

The goal of this study is to evaluate the image quality and clinical utility of the OCTA images from the VG200D OCT device (investigational device) compared against the FA and ICGA images from the UWF Optos California (CA) device. Image assessment will be conducted by three expert image graders and involve the assessment of the images based on both image quality and clinical utility. Evidence for substantial equivalence will be obtained through establishing similar image evaluation results across the devices based on image quality and clinical utility.

Read the detailed description
  1. Protocol Summary

The goal of this study is to evaluate the image quality and clinical utility of the OCTA images from the VG200D OCT device (investigational device) compared against the FA and ICGA images from the UWF Optos California (CA) device. Image assessment will be conducted by three expert image graders and involve the assessment of the images based on both image quality and clinical utility. Evidence for substantial equivalence will be obtained through establishing similar image evaluation results across the devices based on image quality and clinical utility.

Objectives and Endpoints

The primary objective is to evaluate image quality and clinical utility for visualization of the retinal vasculature from en-face OCTA scans between the VG200D and FA and ICGA images from the CA SLO device in eyes with retinal pathology.

The endpoint is the image grading results of the scans of the vascular structure of the retina in eyes with retinal associated pathology.

Methods

This is a prospective comparative study that will be conducted at one clinical site in the United States, in which subjects who sign an informed consent form and fulfil all inclusion and exclusion criteria will have images obtained using the investigational study device and the predicate device (VG200D and CA respectively).

This study will employ one VG200D device and one Optos CA device. At least one acceptable scan will be captured for each subject on each device. Scans will be assessed at the time of capture by the operator for acceptable quality, poor quality scans will be retaken. All scans will be saved and both acceptable and unacceptable scans will be recorded on the CRF. For FA and ICGA scans, the CA device captures multiple images over the time-course of the dye filling the arteries and veins, however the operator and/or investigator will review and choose the most clinically appropriate image to use for evaluation.

Subjects enrolled in this study will be confirmed to have retina associated pathology at the time of the study visit and will be in need of an FA and/or ICGA scan. Ocular status will be confirmed by a clinical examination during the study visit. Subjects enrolled may have more than one ocular pathology. Acceptable retina associated pathologies may include but are not limited to: Age-related macular degeneration, Diabetic Retinopathy with or without DME, and/or Vein or artery occlusions, that require FA or ICGA imaging.

If both eyes qualify, the study eye will be selected by the Investigator based on retinal pathology, where the study eye will have more significant pathology. If only one eye qualifies, that eye will be the study eye. Device imaging order will be randomized.

All scans are reviewed for acceptable image quality by the operator at the time of image acquisition based on user manual described criteria and as described in section 7.1.1 below. Operators will use the pre-defined, objective criteria described in section 7.1.1 below for how images are included into or excluded from the final data set and will be applied by the device operators using pre-defined image quality parameters, such as the signal strength (for OCTA images), poor illumination or contrast (for SLO images), presence of blinks, eye-movements, clipping, etc. These criteria will be applied to all scans at the time of capture by the operator and/or investigator. Acceptable scans will solely be determined by the operator and investigator. The number of scans that are rejected for all devices will be recorded in the CRF and the reasons for rejection will be provided. Image accountability of all scans will be reported in the final clinical study report.

The VG200D has more than one OCTA scan pattern available and all OCTA scan patterns for the VG200D will be captured for image evaluation. The first acceptable OCTA scan from each scan pattern captured will be used for the en-face OCTA visualization assessment.

The en-face OCTA images will be assessed and graded by three experienced graders and scored for image quality and clinical utility as compared to a similar grading of the Optos CA FA and ICGA images.

Image Grading

OCTA en-face images and FA and ICGA images will be exported and evaluated by three masked graders in a masked and randomized fashion for image quality and clinical utility. Image graders will have experience in both OCTA images and FA and ICGA images and will be independent from the clinical research site operator and investigator. Grading will be masked and randomized. Graders will work independently evaluating a single image at a time for the FA and/or ICGA images and will review all OCTA depth slabs for the OCTA scans. For OCTA scans, where multiple images at various depths are available, all depth scans (slabs) will be reviewed together for that patient and an overall image assessment will be provided (i.e., a Gestalt assessment will be made based on all images).

All graders will score each image for general image quality on a five-point scale from 0-5 where scores of 0 indicate image failure, 1 indicates very poor image quality, 2 indicates poor image quality, 3 indicates average image quality, 4 indicates good image quality, and 5 indicates excellent image quality. Scores of 0, 1 and 2 indicate the images have unacceptable image quality, and scores of 3, 4 and 5 indicate the images have acceptable image quality. In addition, images will be graded for clinical utility in helping to aid clinical decisions, such as viewing normal structures (confirming absence of pathology) or detecting pathological changes in the images (confirming pathology). The graders will evaluate clinical utility based on image content (e.g., identifying key vascular features such as the foveal avascular zone border, large-, medium-, and small-sized blood vessels, and blind-end capillaries; key pathologic vascular features such as microaneurysms, neovascular networks, telangiectasias, capillary dropout or nonperfusion, etc. En face depth sections (thickness slabs) from all available depths will be assessed together. The clinical utility or usefulness of OCTA images will also be graded on a five-point scale from 0-5 where scores of 0 indicate no clinical information is present, 1 indicates clinical information is very poor and not helpful, 2 indicates clinical information is poor and not helpful, 3 indicates clinical information is average but helpful, 4 indicates clinical information is good and helpful, and 5 indicates the clinical information present is excellent and very helpful. Scores of 0, 1 and 2 indicate the images are not clinically helpful and are considered unacceptable for providing useful clinical information. Scores of 3, 4 and 5 indicate the images are adding useful clinical information for aiding clinical decisions and are acceptable.

Planned Analyses

Results will be analyzed for differences using the non-parametric Wilcoxon signed rank test. In addition, the percentage agreement between each pair of readers will be determined by using 2x2 tables for the binary outcomes of acceptable vs. not acceptable.

Analysis of Safety Any adverse event (AE) associated with the VG200D or the predicate devices will be used to evaluate safety. Adverse event definitions and reporting requirements are provided in the study Protocol. All adverse events will be reported in the clinical study report.

Being tested
Dream OCT

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dream OCTDevice

    This study employs the Dream OCT to image the eyes of patients with retina pathology

Study groups in NCT07568704
Study groupRoleWhat they receive
Eyes with retina pathologyThese are eyes with some type of retina pathology such as age-related macular degeneration, diabetic retinopathy, diabetic macula edema, and other retina pathologies
Receives: Device: Dream OCT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Image assessment of retinal images

    The outcome measure is the image grading of retinal images including OCTA and FA and or ICGA images as graded by experts

    Measured: All images and clinical study data will be collected in one clinical visit, which typically should take approximately 1 hour.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2026
  2. Study start25 Mar 2026
  3. Primary completion15 Jul 2026 (estimated)
  4. Study completion31 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07568704
Sponsor's protocol ID
DREAM-CP2026-002
Acronym
OCTA & FA
Status last verified
Apr 2026
First submitted
15 Apr 2026
Last updated
6 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Retina Pathology, run by Intalight, Inc at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mike Sinai, PhD (6198067636, mike.sinai@intalight.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Image assessment of retinal images (time frame: All images and clinical study data will be collected in one clinical visit, which typically should take approximately 1 hour.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in